Medications guides.

The two FDA-approved obesity drugs go head to head — efficacy, side effects, cost, insurance coverage, and who each one is actually right for.

How long before conception should you stop Ozempic, Wegovy, or Zepbound? Washout timelines, fertility effects, and what the prescribing information says.

Rapid weight loss on GLP-1s increases gallstone risk. Here's why it happens, warning signs to watch for, and what you can do to reduce your risk.

Reports of depression, suicidal ideation, and mood changes on GLP-1s made headlines in 2023-2024. Here's what the FDA found, what the trials show, and what to watch for.

Rapid weight loss on GLP-1s can change how your face looks — sometimes dramatically. Here's why it happens, what's normal vs concerning, and what dermatologists and plastic surgeons are actually recommending.

The oral version of Wegovy was approved in 2026, giving patients a needle-free path to the same molecule. Here's how it compares to the injection, what the pill actually requires, and who it's best for.

Every GLP-1 carries a black-box warning about thyroid C-cell tumors. It's the most alarming thing on the label — and the most misunderstood. Here's what the data actually shows and who needs to worry.

The FDA has resolved the semaglutide and tirzepatide shortages, and the rules around compounded GLP-1s have changed dramatically. Here's the current landscape — what's still available, what's not, and the risks.

These are the two dominant GLP-1 molecules in 2026. SURMOUNT-5 compared them directly. Here's what the trial showed, what it didn't, and how to decide between them for your situation.

GLP-1 medications must be stopped before pregnancy — but they may actually improve fertility first. Here's the evidence on both sides, the recommended timelines, and why your prescriber needs to be in the loop.

The SELECT trial was the first to prove that a GLP-1 reduces heart attacks and strokes in patients with obesity. Here's what the data shows, who benefits most, and how this changes the insurance and prescribing landscape.

For many GLP-1 patients, the most life-changing effect isn't weight loss — it's the silence. The constant mental chatter about food stops. Here's the neuroscience of food noise, how GLP-1s turn it down, and why it matters more than the scale.

Realistic weight loss expectations on Ozempic, Wegovy, and Zepbound — month by month from your first injection through year two.

The list price is $935/month, but almost nobody pays that. Here's what Ozempic actually costs without insurance — and 6 ways to pay less.

Roughly 25–40% of weight lost on a GLP-1 is lean mass — much of it muscle. That number can be cut substantially with the right protein, training, and dosing approach. Here's the protocol that's working in 2026.

Most people regain a meaningful share of lost weight within a year of stopping a GLP-1. Here's what the data actually shows, why it happens, and the four strategies prescribers are using to make discontinuation work.

Mounjaro and Zepbound are the exact same molecule (tirzepatide) made by the same company. So why two names, two prices, and two sets of insurance rules? Here's what's actually going on — and how to use it to your advantage.

Hair shedding is one of the most upsetting GLP-1 side effects — and one of the most misunderstood. Here's why it happens (the answer is mostly not what you think), how long it lasts, and the interventions that have evidence behind them.

How tirzepatide works, why its results are dramatically better than semaglutide, and whether the price makes it the right pick for you.

Same molecule, two brands, wildly different rules. Here's what actually separates them and what it means for cost, coverage, and who should take which.

The pill finally exists. Here's how it compares on results, price, and who should switch — and who definitely shouldn't.